Oric Pharmaceuticals, Inc.

As of June 30, 2026, Oric Pharmaceuticals, Inc. carries a market capitalization of 983.10M, placing it among publicly traded companies globally. Its enterprise value stands at 754.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Oric Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Oric Pharmaceuticals, Inc. has 103.64M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Oric Pharmaceuticals, Inc. maintains a current ratio of 13.19, meaning it holds 13.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Oric Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -39.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.35, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 106.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Oric Pharmaceuticals, Inc.'s stock has gained approximately 16.63% over the past 52 weeks. The 50-day moving average sits at 11.30, while the 200-day moving average is 9.65.

Over the twelve months ended June 30, 2026, Oric Pharmaceuticals, Inc. generated - - in revenue and converted that into -122.85M in net income, yielding earnings per share of -1.18. EBITDA reached -135.67M, while operating income came in at -136.67M.

As of June 30, 2026, Oric Pharmaceuticals, Inc. holds 231.75M in cash and equivalents against 2.91M in total debt, resulting in a net debt position of -32.81M. Total book value stands at 333.71M, with working capital of 221.40M providing operational flexibility.

Oric Pharmaceuticals, Inc. produced -97.72M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -542,686.00 in capital expenditures, free cash flow totaled -98.26M - equivalent to -0.95 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.98: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.40, meaning Oric Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Oric Pharmaceuticals, Inc. has an Altman Z-Score of 25.58, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.